Systemic therapy for pancreatic cancer

Seminars in Radiation Oncology

Volumn 15, Issue 4 SPEC. ISS., 2005, Pages 245-253

  Ko, Andrew H ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Gemcitabine; Metastatic; Pancreatic cancer; Targeted; Therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; EXATECAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RUBITECAN; TIPIFARNIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; HUMAN; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY;

EID: 25444522497     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.06.001     Document Type: Article

References (70)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. H.A. Burris 3rd, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial J Clin Oncol 15 1997 2403 2413
3. A.M. Storniolo, N.H. Enas, C.A. Brown An investigational new drug treatment program for patients with gemcitabine Results for over 3000 patients with pancreatic carcinoma Cancer 85 1999 1261 1268
4. R. Grunewald, H. Kantarjian, M.J. Keating Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia Cancer Res 50 1990 6823 6826
5. J.L. Abbruzzese, R. Grunewald, E.A. Weeks A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 1991 491 498
6. M. Tempero, W. Plunkett, V. Ruiz Van Haperen Randomized phase II comparison of dose-intense gemcitabine Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
7. F.V. Fossella, S.M. Lippman, D.M. Shin Maximum-tolerated dose defined for single-agent gemcitabine A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer J Clin Oncol 15 1997 310 316
8. R. Brand, M. Capadano, M. Tempero A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors Invest New Drugs 15 1997 331 341
9. N. Touroutoglou, D. Gravel, M.N. Raber Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Ann Oncol 9 1998 1003 1008
10. J.D. Berlin, P. Catalano, J.P. Thomas Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
11. A.M. Bergman, V.W. Ruiz van Haperen, G. Veerman Synergistic interaction between cisplatin and gemcitabine in vitro Clin Cancer Res 2 1996 521 530
12. F. Kanzawa, N. Saijo In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model Semin Oncol 24 1997 S7-8 S7-16
13. F. Cardenal, M.P. Lopez-Cabrerizo, A. Anton Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 17 1999 12 18
14. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
15. M.J. Moore, E.W. Winquist, N. Murray Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer A phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2876 2881
16. D. Kaufman, D. Raghavan, M. Carducci Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921 1927
17. V. Heinemann, H. Wilke, H.G. Mergenthaler Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Ann Oncol 11 2000 1399 1403
18. P.A. Philip, M.M. Zalupski, V.K. Vaitkevicius Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma Cancer 92 2001 569 577
19. G. Colucci, F. Giuliani, V. Gebbia Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
20. V. Heinemann, D. Quietzsch, F. Gieseler A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma 2003 250 Proceedings of the American Society of Clinical Oncology. Chicago, IL
21. C. Louvet, R. Labianca, P. Hammel Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
22. C.M. Rocha Lima, D. Savarese, H. Bruckner Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 2002 1182 1191
23. P. Cheverton, H. Freiss, J. Andras Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC) 2004 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
24. E. O'Reilly, G. Abou-Alfa, R. Letourneau A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer 2004 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
25. K.D. Miller, J. Picus, C. Blanke Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer Ann Oncol 11 2000 101 103
26. D.A. Richards, H.L. Kindler, H. Oettle A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer 2004 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
27. M.H. Kulke, D. Niedzwiecki, M.A. Tempero A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904), Proceedings of the American Society of Clinical Oncology 2004 315 New Orleans, La
28. P. Rougier, A. Adenis, M. Ducreux A phase II study Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma Eur J Cancer 36 2000 1016 1025
29. J.E. Kurtz, S. Negrier, F. Husseini A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer Hepatogastroenterology 50 2003 567 570
30. B. Burtness, R. Sipples, G. Mirto Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer 2004 341 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
31. T.H. Cartwright, A. Cohn, J.A. Varkey Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 2002 160 164
32. V. Hess, M. Salzberg, M. Borner Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma A phase I/II trial J Clin Oncol 21 2003 66 68
33. W. Scheithauer, B. Schüll, H. Ulrich-Pur Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma 2002 126a Proceedings of the American Society of Clincal Oncology. Orlando, FL
34. L.T. Campos, R.H. Alvarez, D.B. Sanford Gemcitabine and capecitabine An active regimen in patients with advanced pancreatic cancer 2003 373 Proceedings of the American Society of Clinical Oncology. Chicago, IL
35. R.L. Fine, D.R. Fogelman, S. Schreibman GTX chemotherapy for metastatic pancreatic cancer Response, survival, and toxicity data 2004 379 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
36. V.A. Heinemann, A. Golf, G. Seipelt Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer 2004 339 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
37. M.M. Konstadoulakis, P.T. Antonakis, B.G. Tsibloulis A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 48 2001 417 420
38. J.S. Stehlin, B.C. Giovanella, E.A. Natelson A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer Int J Oncol 14 1999 821 831
39. A.D. Jacobs, H.A. Burris, S. Rivkin A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study 2004 315 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
40. M.J. Moore, J. Hamm, J. Dancey Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296 3302
41. S.R. Bramhall, J. Schulz, J. Nemunaitis A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
42. S.R. Bramhall, A. Rosemurgy, P.D. Brown Marimastat as first-line therapy for patients with unresectable pancreatic cancer A randomized trial J Clin Oncol 19 2001 3447 3455
43. E. Van Cutsem, H. van de Velde, P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
44. J. Mendelsohn, J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
45. H.Q. Xiong, A. Rosenberg, A. LoBuglio Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer A multicenter phase II Trial J Clin Oncol 22 2004 2610 2616
46. T.E. Kim, J.R. Murren Erlotinib OSI/Roche/Genentech Curr Opin Investig Drugs 3 2002 1385 1395
47. T. Dragovich, A. Patnaik, E.K. Rowinsky A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies 2003 223 Proceedings of the American Society of Clincal Oncology. Chicago, IL
48. B.W. Porterfield, T. Dragovich, A. Patnaik Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma Results from a phase IB trial 2004 339 Proceedings of the American Society of Clincal Oncology. New Orleans, LA
49. M.J. Moore, D. Goldstein, J. Hamm Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, Proceedings of the 2005 Gastrointestinal Cancers Symposium 2004 121 Hollywood, FL
50. M. Korc Pathways for aberrant angiogenesis in pancreatic cancer Mol Cancer 2 2003 8
51. J. Luo, P. Guo, K. Matsuda Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo Int J Cancer 92 2001 361 369
52. J. Itakura, T. Ishiwata, B. Shen Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer Int J Cancer 85 2000 27 34
53. N. Ikeda, M. Adachi, T. Taki Prognostic significance of angiogenesis in human pancreatic cancer Br J Cancer 79 1999 1553 1563
54. J. Itakura, T. Ishiwata, H. Friess Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression Clin Cancer Res 3 1997 1309 1316
55. Y. Seo, H. Baba, T. Fukuda High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer 88 2000 2239 2245
56. H.G. Hotz, H.A. Reber, B. Hotz Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth J Gastrointest Surg 5 2001 131 138
57. T. Tokunaga, Y. Abe, T. Tsuchida Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line Int J Oncol 21 2002 1027 1032
58. T. Hoshida, M. Sunamura, D.G. Duda Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor Pancreas 25 2002 111 121
59. T. Ogawa, K. Takayama, N. Takakura Anti-tumor angiogenesis therapy using soluble receptors Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor Cancer Gene Ther 9 2002 633 640
60. H.L. Kindler, G. Friberg, W.M. Stadler Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC) Updated results of a multi-center phase II trial 2004 314 Proceedings of the American Society of Clinical Oncology. New Orleans, LA
61. C.G. Moertel, S. Frytak, R.G. Hahn Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1981 1705 1710
62. D.J. Klaassen, J.M. MacIntyre, G.E. Catton Treatment of locally unresectable cancer of the stomach and pancreas a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study J Clin Oncol 3 1985 373 378
63. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
64. V. Heinemann, M.M. Schermuly, P. Stieber CA19-9 A predictor of response in pancreatic cancer treated with gemcitabine and cisplatin Anticancer Res 19 1999 2433 2435
65. U. Halm, T. Schumann, I. Schiefke Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer Br J Cancer 82 2000 1013 1016
66. A.H. Ko, F.G. Renshaw, J. Hwang Prognostic value of CA19-9 in patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine 2003 259 Proceedings of the American Society of Clinical Oncology. Chicago, IL
67. C. Almoguera, D. Shibata, K. Forrester Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 1988 549 554
68. T. Hirano, Y. Shino, T. Saito Dominant negative MEKK1 inhibits survival of pancreatic cancer cells Oncogene 21 2002 5923 5928
69. H. Friess, P. Berberat, M. Schilling Pancreatic cancer The potential clinical relevance of alterations in growth factors and their receptors J Mol Med 74 1996 35 42
70. S.P. Thayer, M.P. Di Magliano, P.W. Heiser Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 425 2003 851 856